Gentel prepares to launch APiX platform, assays in H1 as it looks to build services arm

Gentel prepares to launch APiX platform, assays in H1 as it looks to build services arm

Gentel Biosciences, a nine-year-old privately held protein-array firm based in Madison, Wis., is planning to launch assays for carbohydrate and protein biomarker profiling this month, and to debut a new high-throughput microarray platform called APiX in June, according to a company official.
Dan Clutter, Gentel’s new vice president of commercial development, told BioArray News last week that the firm believes its APiX assays and platform will be attractive to both its core pharma customers, who are interested in adding new assays to compound screening programs, and to new academic customers, who might be attracted to the system’s lower cost.
Read full article>>